Decoste S D, Boudreaux C, Dover J S
Department of Dermatology, Harvard Medical School, Boston, Mass.
Arch Dermatol. 1990 Oct;126(10):1324-9.
Graft-vs-host disease can develop in immunosuppressed individuals who receive blood-product transfusions that contain immunocompetent lymphocytes. We report two cases of fatal transfusion-associated graft-vs-host disease that developed in patients with Hodgkin's disease who were undergoing therapy. We review all cases of this entity in patients with malignancies, represented predominantly by patients with hematologic malignancies. The groups at risk for development of transfusion-associated graft-vs-host disease, the clinical presentation and course, and methods of diagnosis are summarized. Prevention of this highly fatal condition is possible by irradiation of blood products given to patients at risk, but problems remain in determining the groups that warrant such measures. Dermatologists need to have heightened awareness of this entity to facilitate more complete diagnosis and allow establishment of effective standards of care.
移植物抗宿主病可发生于接受含有免疫活性淋巴细胞的血液制品输血的免疫抑制个体。我们报告了两例在接受治疗的霍奇金病患者中发生的致命性输血相关移植物抗宿主病病例。我们回顾了以血液系统恶性肿瘤患者为主的所有恶性肿瘤患者中该疾病的病例。总结了发生输血相关移植物抗宿主病的高危人群、临床表现和病程以及诊断方法。对有风险的患者给予照射过的血液制品可预防这种高度致命的疾病，但在确定需要采取此类措施的人群方面仍存在问题。皮肤科医生需要提高对该疾病的认识，以促进更全面的诊断并建立有效的护理标准。
